交易 Cogent Biosciences, Inc. - COGT CFD
新增到我的最愛- 摘要
- 曆史數據
- 活動
- 盈虧控制
- 資産負債表
- 現金流
交易條件
價差 | 0.08 | ||||||||
多頭倉位隔夜費用
多頭隔夜費用
前往平台 | -0.026179% | ||||||||
空頭倉位隔夜費用
空頭隔夜費用
前往平台 | 0.003957% | ||||||||
隔夜費時間 | 21:00 (UTC) | ||||||||
最小成交量 | 1 | ||||||||
貨幣 | USD | ||||||||
保證金 | 5% | ||||||||
股票交易 | United States of America | ||||||||
交易委員會 | 0% |
*Information provided by Capital.com
Cogent Biosciences Inc ESG Risk Ratings
High Medium Low Negligible
“B”分數表示相對 ESG 表現良好,公開報告重要 ESG 數據的透明度高於平均水平。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 拋售 | 自訂 | 變化 (%) | 打開 | 最高 | 最小 |
---|---|---|---|---|---|---|
Mar 28, 2024 | 6.68 | 0.29 | 4.54% | 6.39 | 6.73 | 6.36 |
Mar 27, 2024 | 6.48 | 0.62 | 10.58% | 5.86 | 6.48 | 5.83 |
Mar 26, 2024 | 5.79 | 0.02 | 0.35% | 5.77 | 5.99 | 5.74 |
Mar 25, 2024 | 5.73 | -0.57 | -9.05% | 6.30 | 6.35 | 5.69 |
Mar 22, 2024 | 6.35 | -0.24 | -3.64% | 6.59 | 6.70 | 6.35 |
Mar 21, 2024 | 6.62 | -0.15 | -2.22% | 6.77 | 6.92 | 6.60 |
Mar 20, 2024 | 6.79 | 0.13 | 1.95% | 6.66 | 7.01 | 6.45 |
Mar 19, 2024 | 6.67 | 0.19 | 2.93% | 6.48 | 6.73 | 6.48 |
Mar 18, 2024 | 6.69 | 0.00 | 0.00% | 6.69 | 6.93 | 6.61 |
Mar 15, 2024 | 7.01 | 0.56 | 8.68% | 6.45 | 7.34 | 6.45 |
Mar 14, 2024 | 6.51 | -0.13 | -1.96% | 6.64 | 6.78 | 6.36 |
Mar 13, 2024 | 6.53 | 0.26 | 4.15% | 6.27 | 6.76 | 6.27 |
Mar 12, 2024 | 6.31 | -0.11 | -1.71% | 6.42 | 6.50 | 6.14 |
Mar 11, 2024 | 6.46 | -0.11 | -1.67% | 6.57 | 6.66 | 6.43 |
Mar 8, 2024 | 6.56 | -0.10 | -1.50% | 6.66 | 6.96 | 6.46 |
Mar 7, 2024 | 6.67 | -0.10 | -1.48% | 6.77 | 6.99 | 6.65 |
Mar 6, 2024 | 6.85 | -0.13 | -1.86% | 6.98 | 7.08 | 6.70 |
Mar 5, 2024 | 7.00 | 0.10 | 1.45% | 6.90 | 7.26 | 6.87 |
Mar 4, 2024 | 7.05 | -0.23 | -3.16% | 7.28 | 7.44 | 7.00 |
Mar 1, 2024 | 7.23 | 0.18 | 2.55% | 7.05 | 7.38 | 6.99 |
Cogent Biosciences, Inc. Events
時間 (UTC) | 國家 | 事件 |
---|---|---|
Tuesday, May 7, 2024 | ||
時間 (UTC) 12:30 | 國家 US
| 事件 Q1 2024 Cogent Biosciences Inc Earnings Release Q1 2024 Cogent Biosciences Inc Earnings ReleaseForecast(預報) -返回 - |
Thursday, June 6, 2024 | ||
時間 (UTC) 13:00 | 國家 US
| 事件 Cogent Biosciences Inc Annual Shareholders Meeting Cogent Biosciences Inc Annual Shareholders MeetingForecast(預報) -返回 - |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 0 | 0 | 7.871 | 22.499 | 9.734 |
收入 | 0 | 7.871 | 22.499 | 9.734 | |
總營業費用 | 148.239 | 75.551 | 90.07 | 54.677 | 45.739 |
銷售/一般/行政費用,總計 | 26.212 | 19.638 | 17.422 | 10.968 | 7.454 |
研究與開發 | 121.627 | 55.913 | 72.648 | 43.709 | 38.285 |
營業收入 | -148.239 | -75.551 | -82.199 | -32.178 | -36.005 |
利息收入(費用),非經營淨值 | 3.989 | 0.467 | 0.144 | 0.267 | 1.153 |
其他,淨值 | 4.009 | 2.811 | -0.246 | 0.078 | 0.32 |
稅前淨收入 | -140.241 | -72.273 | -74.808 | -31.833 | -34.532 |
稅後淨收入 | -140.241 | -72.273 | -74.808 | -31.833 | -34.532 |
未計算非常項目前的淨收益 | -140.241 | -72.273 | -74.808 | -31.833 | -34.532 |
淨收入 | -140.241 | -72.273 | -74.808 | -31.833 | -34.532 |
Total Adjustments to Net Income | 0 | -104.4 | 0 | -0.016 | |
普通股股東可獲收益 (不含非經常性項目) | -140.241 | -72.273 | -179.208 | -31.833 | -34.548 |
普通股股東可獲收益 (含非經常性項目) | -140.241 | -72.273 | -179.208 | -31.833 | -34.548 |
攤薄淨收入 | -140.241 | -72.273 | -179.208 | -31.833 | -34.548 |
攤薄後加權平均股 | 58.7397 | 38.7308 | 11.0813 | 7.62008 | 6.22392 |
扣除特別項目的每股攤薄盈利 | -2.3875 | -1.86603 | -16.1722 | -4.17751 | -5.55084 |
Dividends per Share - Common Stock Primary Issue | |||||
每股正常攤薄盈利 | -2.38069 | -1.86603 | -16.4693 | -4.17751 | -5.55084 |
Gain (Loss) on Sale of Assets | 0 | 7.493 | |||
異常費用(收入) | 0.4 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 0 | 0 | 0 | 0 | 0 |
收入 | |||||
總營業費用 | 47.085 | 43.237 | 43.745 | 37.221 | 35.855 |
銷售/一般/行政費用,總計 | 8.214 | 7.199 | 7.003 | 6.885 | 6.376 |
研究與開發 | 38.871 | 36.038 | 36.742 | 29.936 | 29.479 |
營業收入 | -47.085 | -43.237 | -43.745 | -37.221 | -35.855 |
利息收入(費用),非經營淨值 | 2.741 | 2.268 | 2.11 | 1.5 | 0.272 |
其他,淨值 | 0.268 | 2.382 | 2.017 | 0.659 | 0.656 |
稅前淨收入 | -44.076 | -38.587 | -39.618 | -35.062 | -34.927 |
稅後淨收入 | -44.076 | -38.587 | -39.618 | -35.062 | -34.927 |
未計算非常項目前的淨收益 | -44.076 | -38.587 | -39.618 | -35.062 | -34.927 |
淨收入 | -44.076 | -38.587 | -39.618 | -35.062 | -34.927 |
普通股股東可獲收益 (不含非經常性項目) | -44.076 | -38.587 | -39.618 | -35.062 | -34.927 |
普通股股東可獲收益 (含非經常性項目) | -44.076 | -38.587 | -39.618 | -35.062 | -34.927 |
攤薄淨收入 | -44.076 | -38.587 | -39.618 | -35.062 | -34.927 |
攤薄後加權平均股 | 74.7533 | 70.7349 | 70.6187 | 69.5764 | 49.3889 |
扣除特別項目的每股攤薄盈利 | -0.58962 | -0.54552 | -0.56101 | -0.50394 | -0.70718 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | -0.58962 | -0.54552 | -0.56101 | -0.49819 | -0.70718 |
Gain (Loss) on Sale of Assets | |||||
Total Adjustments to Net Income | |||||
異常費用(收入) | 0 | 0.4 |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 264.966 | 222.633 | 244.912 | 40.591 | 81.002 |
現金和短期投資 | 259.276 | 219.684 | 242.19 | 37.424 | 78.594 |
現金等價物 | 139.886 | 219.684 | 242.19 | 37.424 | 55.671 |
短期投資 | 119.39 | 0 | 22.923 | ||
應收賬款總額,淨額 | 0 | 2 | 1.668 | ||
應收賬款 - 貿易,淨額 | 0 | 2 | 1.668 | ||
預付的費用 | 4.435 | 2.949 | 2.722 | 1.167 | 0.74 |
其他流動資産,總計 | 1.255 | 0 | |||
總資産 | 300.81 | 232.092 | 250.916 | 49.423 | 85.927 |
物業/廠房/設備,總計 - 淨額 | 31.099 | 4.477 | 4.749 | 7.15 | 3.251 |
物業/廠房/設備,總計 - 總額 | 32.5 | 5.036 | 5.161 | 11.781 | 6.747 |
累計折舊,總計 | -1.401 | -0.559 | -0.412 | -4.631 | -3.496 |
其他長期資産,總計 | 4.745 | 4.982 | 1.255 | 1.682 | 1.674 |
流動負債總額 | 26.849 | 17.077 | 13.094 | 13.248 | 24.945 |
應付賬款 | 5.842 | 3.483 | 0.732 | 3.183 | 1.519 |
預提費用 | 18.903 | 10.299 | 5.847 | 7.856 | 3.798 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 2.104 | 3.295 | 6.515 | 2.209 | 19.628 |
負債總額 | 45.075 | 17.908 | 16.249 | 17.661 | 25.693 |
長期債務總額 | 0 | 0 | 0 | 0 | 0 |
其他負債,總計 | 18.226 | 0.831 | 3.155 | 4.413 | 0.748 |
股權 | 255.735 | 214.184 | 234.667 | 31.762 | 60.234 |
Preferred Stock - Non Redeemable, Net | |||||
普通股 | 0.07 | 0.044 | 0.032 | 0.03 | 0.03 |
額外實收資本 | 601.153 | 399.713 | 322.454 | 155.624 | 152.275 |
留存收益(累計赤字) | -411.214 | -270.973 | -198.7 | -123.892 | -92.059 |
其他權益,總計 | -0.104 | 0 | -0.012 | ||
總負債和股東權益 | 300.81 | 232.092 | 250.916 | 49.423 | 85.927 |
已發行普通股總數 | 69.8934 | 43.8059 | 32.3479 | 7.66576 | 7.51449 |
Redeemable Preferred Stock | 65.83 | 85.4 | 110.881 | 0 | 0 |
Total Preferred Shares Outstanding | 0.08105 | 0.10329 | 0.13224 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 285.953 | 334.519 | 226.27 | 264.966 | 296.417 |
現金和短期投資 | 279.041 | 329.399 | 220.264 | 259.276 | 289.094 |
現金等價物 | 86.81 | 214.317 | 160.698 | 139.886 | 140.568 |
預付的費用 | 6.912 | 5.12 | 4.751 | 4.435 | 6.068 |
總資産 | 355.446 | 392.369 | 263.198 | 300.81 | 331.56 |
物業/廠房/設備,總計 - 淨額 | 30.837 | 31.563 | 32.153 | 31.099 | 30.375 |
其他長期資産,總計 | 4.862 | 4.775 | 4.775 | 4.745 | 4.768 |
流動負債總額 | 34.719 | 25.757 | 21.12 | 26.849 | 23.551 |
應付賬款 | 9.868 | 7.161 | 4.172 | 5.842 | 4.093 |
預提費用 | 24.393 | 18.1 | 15.933 | 18.903 | 15.201 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 0.458 | 0.496 | 1.015 | 2.104 | 4.257 |
負債總額 | 52.548 | 43.941 | 39.635 | 45.075 | 41.618 |
長期債務總額 | 0 | 0 | 0 | 0 | 0 |
其他負債,總計 | 17.829 | 18.184 | 18.515 | 18.226 | 18.067 |
股權 | 302.898 | 348.428 | 223.563 | 255.735 | 289.942 |
Redeemable Preferred Stock | 60.035 | 62.31 | 62.31 | 65.83 | 65.83 |
普通股 | 0.086 | 0.085 | 0.071 | 0.07 | 0.07 |
額外實收資本 | 792.208 | 780.007 | 610.967 | 601.153 | 595.801 |
留存收益(累計赤字) | -549.259 | -493.877 | -449.801 | -411.214 | -371.596 |
總負債和股東權益 | 355.446 | 392.369 | 263.198 | 300.81 | 331.56 |
已發行普通股總數 | 86.1243 | 85.3342 | 70.9468 | 69.8934 | 69.858 |
Total Preferred Shares Outstanding | 0.07447 | 0.07705 | 0.07705 | 0.08105 | 0.08105 |
其他流動資産,總計 | 0 | 0 | 1.255 | 1.255 | 1.255 |
短期投資 | 192.231 | 115.082 | 59.566 | 119.39 | 148.526 |
其他權益,總計 | -0.172 | -0.097 | 0.016 | -0.104 | -0.163 |
長期投資 | 33.794 | 21.512 |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
淨收入/起跑線 | -140.241 | -72.273 | -74.808 | -31.833 | -34.532 |
經營活動産生的現金 | -118.638 | -58.763 | -35.85 | -41.514 | -32.489 |
經營活動産生的現金 | 0.842 | 0.147 | 0.72 | 1.293 | 1.321 |
非現金物品 | 20.01 | 11.343 | 43.554 | 3.11 | 2.875 |
營運資金的變化 | 0.751 | 2.02 | -5.316 | -14.084 | -2.153 |
投資活動産生的現金 | -124.718 | -1.719 | 8.42 | 23.159 | -10.531 |
資本支出 | -6.863 | -1.719 | 0 | -0.033 | -0.549 |
其他投資現金流量項目,總計 | -117.855 | 0 | 8.42 | 23.192 | -9.982 |
融資活動産生的現金 | 163.558 | 37.976 | 232.196 | 0.108 | 70.346 |
融資現金流項目 | 0 | -0.085 | -2.056 | ||
股票的發行(報廢),淨額 | 163.558 | 38.061 | 232.196 | 0.108 | 72.402 |
現金淨變化 | -79.798 | -22.506 | 204.766 | -18.247 | 27.326 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -38.587 | -140.241 | -100.623 | -65.561 | -30.634 |
Cash From Operating Activities | -39.517 | -118.638 | -89.23 | -54.79 | -28.334 |
Cash From Operating Activities | 0.529 | 0.842 | 0.422 | 0.166 | 0.069 |
Non-Cash Items | 3.301 | 20.01 | 16.998 | 9.773 | 4.666 |
Changes in Working Capital | -4.76 | 0.751 | -6.027 | 0.832 | -2.435 |
Cash From Financing Activities | 0.445 | 163.558 | 163.243 | 162.253 | 0.138 |
Financing Cash Flow Items | 0 | 0 | 0 | ||
Issuance (Retirement) of Stock, Net | 0.445 | 163.558 | 163.243 | 162.253 | 0.138 |
Net Change in Cash | 20.812 | -79.798 | -79.116 | 105.878 | -28.637 |
Cash From Investing Activities | 59.884 | -124.718 | -153.129 | -1.585 | -0.441 |
Capital Expenditures | -1.103 | -6.863 | -4.896 | -1.585 | -0.441 |
Other Investing Cash Flow Items, Total | 60.987 | -117.855 | -148.233 |
差價合約交易計算器
計算您的假設損益
交易佣金
0
- 1:1
槓桿
1:1
- 20
- 100
- 500
- 1000
- 10000
交易
交易規模(槓桿 x 投資):
打開
拋售
已賣出 做多
Industry: | Bio Therapeutic Drugs |
275 Wyman Street
3rd Floor
WALTHAM
MASSACHUSETTS 02451
US
盈虧控制
- Annual
- Quarterly
人們也觀看
還在尋找值得信賴的經紀商?
加入全球 580.000 多名交易者,選擇與 Capital.com 交易